Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease

Phase 2OntunisertibNeutral

AI Analysis

Summary

Agomab Therapeutics announced the Phase 2b study design for NOV-ERA evaluating Ontunisertib in fibrostenosing Crohn's disease. The announcement represents a routine clinical development update with no trial data or regulatory decision.

Clinical Trial Data

Phase

Importance:4/10

Sentiment:

0.00

clinical trialPhase 2bstudy designCrohn's diseasegastroenterology

Related Companies

$AGMB

Read the original article

Published by yahoo_finance on June 23, 2026 9:32 PM

Read Original